Yan HC, Liu Y, Feng Y, Li JM, Sheng LM, Chen X, Xie YP, Li N. Efficacy of disitamab vedotin-containing therapy in metastatic colorectal cancer: A case report. World J Clin Oncol 2025; 16(3): 99527 [DOI: 10.5306/wjco.v16.i3.99527]
Corresponding Author of This Article
Na Li, PhD, Department of Oncology, West China School of Public Health and West China Fourth Hospital, Sichuan University, No. 18 Section 3, Renmin South Road, Chengdu 610041, Sichuan Province, China. 281422934@qq.com
Research Domain of This Article
Oncology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Oncol. Mar 24, 2025; 16(3): 99527 Published online Mar 24, 2025. doi: 10.5306/wjco.v16.i3.99527
Efficacy of disitamab vedotin-containing therapy in metastatic colorectal cancer: A case report
Hu-Cheng Yan, Yan Liu, You Feng, Jun-Ming Li, Lei-Ming Sheng, Xin Chen, Yu-Ping Xie, Na Li
Hu-Cheng Yan, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, Sichuan Province, China
Hu-Cheng Yan, Yan Liu, You Feng, Lei-Ming Sheng, Xin Chen, Yu-Ping Xie, Na Li, Department of Oncology, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China
Jun-Ming Li, Department of Radiology, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China
Author contributions: Li N constructed this work and revised the manuscript; Yan HC contributed to reviewing and editing the manuscript; Li JM, Liu Y, Sheng LM, Chen X, and Xie YP provided valuable recommendations; Feng Y and Sheng LM participated in data analysis; and all authors have read and approved the final manuscript.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Na Li, PhD, Department of Oncology, West China School of Public Health and West China Fourth Hospital, Sichuan University, No. 18 Section 3, Renmin South Road, Chengdu 610041, Sichuan Province, China. 281422934@qq.com
Received: July 24, 2024 Revised: November 10, 2024 Accepted: December 30, 2024 Published online: March 24, 2025 Processing time: 180 Days and 21.2 Hours
Abstract
BACKGROUND
Colorectal cancer (CRC) is a leading cause of cancer-related mortality worldwide. In cases of metastatic CRC (mCRC) that are resistant to conventional chemotherapy-based treatments, the efficacy of available therapeutic options is typically low. CRC exhibiting overexpression or amplification of the human epidermal growth factor receptor 2 (HER2) gene has shown responsiveness to HER2-targeted therapies.
CASE SUMMARY
We present the case of a 69-year-old woman diagnosed with mCRC with an NRAS p.G12V mutation and microsatellite stability, identified through tumor sequencing, along with HER2 overexpression detected by immunohistochemistry. She exhibited an excellent response to disitamab vedotin-containing therapy. To our knowledge, this is the first reported case of mCRC with HER2 overexpression and an NRAS p.G12V mutation achieving a remarkable clinical response to anti-HER2 therapy.
CONCLUSION
Disitamab vedotin demonstrates promising anti-tumor effects in HER2-overexpressing mCRC, offering patients an additional treatment option.
Core Tip: Colorectal cancer (CRC) is a leading cause of cancer-related mortality. In cases of metastatic CRC (mCRC) that is resistant to conventional chemotherapy, human epidermal growth factor receptor 2 (HER2)-targeted therapies have shown promise. We describe a 69-year-old woman with HER2-overexpressing mCRC, featuring an NRAS p.G12V mutation and microsatellite stability, who achieved an excellent response to disitamab vedotin treatment. This case is notable as it is the first recorded observation of a notable clinical response to anti-HER2 therapy in an mCRC patient with HER2 overexpression and an NRAS p.G12V mutation.
